Some of the toughest cancers to treat — pancreatic, ovarian, prostate, glioblastoma — are called "cold" tumors because they attract few immune cells. A new study from Dana-Farber Cancer Institute, published in Immunity, reveals a key reason why: these tumors don't just evade the immune system, they actively hide from it by failing to display recognizable targets on their surface.

The culprit, in many cases, is a faulty p53 protein. Mutations in TP53 occur in roughly half of all human cancers, making it a prime immunotherapy target in theory. But the study found that most p53 mutations are poorly "processed" into surface-displayed peptides that T cells can actually detect. One enzyme, ERAP1, was found to destroy potentially immunogenic p53 fragments before they could be shown to T cells — and blocking ERAP1 in lab experiments restored immune recognition of cancer cells.

The researchers propose a concept called an "immunopeptidome shift" — using drugs to deliberately change what peptides a tumor displays, essentially forcing it out of hiding and turning it "hot." This could work alongside checkpoint inhibitors, cancer vaccines, or engineered T-cell therapies.

Key Takeaways:

• Predicting immune targets from tumor DNA alone is insufficient — peptides must be stably displayed on the cell surface to be actionable
• ERAP1 inhibition restored T-cell recognition of p53-mutant cancer cells in lab models
• The strategy extends beyond p53 and could apply to many solid tumor types
• This research is mechanistic and experimental; no drug has yet converted cold human tumors hot in patients

Why it matters: This research reframes the immunotherapy challenge — instead of only boosting immune cells, we may also need to make tumors more "visible." That shift in thinking could unlock new treatment paths for cancers that have long resisted immunotherapy.